, 22F*, 23F, 33F*) was evaluated in adults ≥65 years of age previously vaccinated with PPV23.
Methods. Study subjects who received PPV23 at least 1 year prior to study entry received a single dose of either PCV-15 or PCV-13 (125/arm) and were followed for safety for 14 days postvaccination. Serotype-specific Immunoglobulin G (IgG) geometric mean concentrations (GMCs) and opsonophagocytic activity (OPA) geometric mean titers (GMTs) were measured immediately prior and 30 days postvaccination. NCT02573081
Results. Safety profiles were comparable between PCV-15 and PCV-13 recipients. Following vaccination, serotype-specific antibody responses for the 13 shared serotypes were generally comparable between recipients of PCV-15 and PCV-13 for IgG GMCs and geometric mean fold rises (GMFRs), OPA GMTs and GMFRs, and percentages of subjects with ≥4-fold-rise from baseline. Recipients of PCV-15 had numerically higher IgG GMCs and OPA GMTs than PCV-13 recipients for two serotypes unique to PCV-15 (22F, 33F).
Conclusion. PCV-15 was generally well tolerated when given as a single dose to adults ≥65 years of age previously vaccinated with PPV23. Following vaccination, serotype-specific IgG GMCs and OPA GMTs were comparable between recipients of PCV-15 and PCV-13 for 13 shared serotypes.
* Background. The effectiveness of the quadrivalent live attenuated influenza vaccine (LAIV4) and inactivated influenza vaccines (IIV) has been evaluated in recent seasons using a number of different study designs (e.g., randomized controlled studies [RCT] , cohort studies and test-negative case-control [TNCC] studies). Effectiveness estimates from these studies have, in general, had very broad confidence intervals reflecting the small numbers of cases reported. We conducted a meta-analysis to more precisely estimate the effectiveness of both vaccine types for the 2016-2017 season.
Methods. LAIV4 and IIV efficacy and effectiveness studies conducted over the 2016-2017 influenza season were identified from the published literature and through personal communication with the study investigators. Effectiveness estimates from all available study designs were included in the meta-analysis to maximize use of all available data and because all studies included methods to minimize bias. The analysis provided average estimates of the LAIV4 and IIV efficacy across countries. A sensitivity analysis limited to TNCC studies was also conducted. Only effectiveness results for A/H3N2 strains were combined as circulation of other strains was minimal. The meta-analyses used a random effects model. Heterogeneity testing was performed.
Results. Seven studies conducted in children in the United States, Japan, Finland, Germany, thr UK, and Canada were identified including four TNCC studies, one cohort study and one RCT (Figure 1 ). Individual effectiveness estimates ranged from 29% to 74% for LAIV4 and from 31% to 56% for IIV. Heterogeneity testing for H3N2 strains was not statistically significant. The consolidated effectiveness estimate across studies for LAIV4 was 44% (95% CI: 24, 58) and for IIV was 45% (95% CI: 29, 58). Estimates for the sensitivity analysis limited to TNCC studies were 61% (95% CI: 40, 74) and 43% (95% CI: 32, 52) for LAIV4 and IIV, respectively.
Conclusion. Despite variability in estimates across studies, both LAIV4 and IIV showed moderate and comparable effectiveness in children for circulating H3N2 strains during the 2016-2017 influenza season.
